Investor FAQs

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting® System, selectively reduces stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is clinically proven to reduce fat bulges in a 60-minute procedure, allowing patients to achieve noticeable and measurable aesthetic results.

You can locate a treatment center by clicking here.

ZELTIQ is headquartered in Pleasanton, CA.

ZELTIQ was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, the Company changed its name to ZELTIQ Aesthetics, Inc.

ZELTIQ's ticker is ZLTQ.

ZELTIQ trades on the NASDAQ under the ticker symbol "ZLTQ".

J.P. Morgan Securities LLC and Goldman, Sachs & Co. were joint bookrunners. William Blair & Company LLC and Canaccord Genuity Inc. acted as co-managers for the offering.

Annual Shareholder Meeting:

Thursday 6/19 at 9am-10am

Four Points by Sheraton

5115 Hopyard Rd.

Pleasanton, CA  94588

San Ramon C & D Room

No, ZELTIQ does not offer a direct stock purchase program.

ZELTIQ's fiscal year end is December 31.

ZELTIQ's independent auditor is PricewaterhouseCoopers LLP.

ZELTIQ's outside legal counsel is Cooley LLP.

The biographies of ZELTIQ's officers and directors are available in the corporate governance section of the website: Board of Directors and Management Team.


All of ZELTIQ's filings can be found in the SEC Filings section of the company's website.

ZELTIQ's closed its initial public offering of 7,000,000 shares at a price of $13 per share on October 18, 2011.

Please submit your question using the form below.

* Indicates required field

Fear No Mirror®